Related Experiment Video
Updated: Jun 20, 2026
10:33
Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
Published on: October 15, 2018
Mutations in the gene encoding DMT1: clinical presentation and treatment
Achille Iolascon1, Luigia De Falco
1CEINGE, Advanced Biotechnologies, Naples; and Department of Biochemistry and Medical Biotechnologies, University Federico II, Naples, Italy. iolascon@ceinge.unina.it
Seminars in Hematology
|September 30, 2009
Summary
Divalent metal transporter 1 (DMT1) deficiency causes severe anemia at birth. Treatment with erythropoietin (Epo) may help, but doesn't fix iron utilization, and liver iron overload is a concern.
Area of Science:
- Biochemistry
- Genetics
- Hematology
Background:
- Divalent metal transporter 1 (DMT1) is crucial for iron absorption and transport.
- DMT1 plays a central role in iron metabolism and is tightly regulated.
- Recent case studies describe patients with DMT1 deficiency.
Purpose of the Study:
- To analyze the role of DMT1 in iron metabolism.
- To review the causes and consequences of DMT1 reduction in animal models and humans.
- To define appropriate treatment for human DMT1 deficiency.
Main Methods:
- Literature review of animal models and human cases of DMT1 deficiency.
- Analysis of clinical presentation, diagnostic markers, and treatment responses.
- Evaluation of iron metabolism and erythropoiesis in affected individuals.
Main Results:
- DMT1 deficiency presents as severe microcytic anemia at birth.
- Diagnostic markers include high serum iron, normal TIBC, increased Tf saturation, elevated ferritin, and increased sTfR.
- Patients responded to erythropoietin (Epo), but MCV/MCH unchanged, suggesting reduced apoptosis rather than improved iron utilization; liver iron overload was noted.
Conclusions:
- DMT1 is essential for iron homeostasis.
- Epo treatment may alleviate anemia in DMT1 deficiency by affecting erythropoiesis, not iron utilization.
- Liver iron overload is a significant consequence requiring management.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:31Translation
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life